Alnylam Pharmaceuticals ALNY Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81%-0.8pp | 81.8%-2.3pp | 84%+0.2pp | 83.9%-2.4pp | 86.3%-0.1pp | |
| Operating margin | 17.5%+4.0pp | 13.5%+5.3pp | 8.2%+15.6pp | -7.3%-2.4pp | -4.9%+3.0pp | |
| Net margin | 11.7%+4.2pp | 7.5%+4.9pp | 2.6%+13.9pp | -11.4%-1.6pp | -9.8%+2.6pp | |
| Returns | ||||||
| Return on equity | 66.9%+2.0pp | 65%+2.8pp | 62.2%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.1× | 0.8×+0.1× | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.1×+0.4× | 2.8×+0.2× | 2.5×-0.3× | 2.8×-0.2× | 3×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.1× | 0.3×-0.8× | 1.1×+0.1× | 1.1×+0.4× | 0.6×-3.4× | |
| Net debt / EBITDA | -1.8×+0.7× | -2.5×+1.3× | -3.8×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $7.78+32.8% | $5.86+244% | $1.70-11.2% | $1.92-41.6% | $3.29+525% | |
| Valuation | ||||||
| Market capitalization | $43.88B-16.5% | $52.54B-12.1% | $59.77B+41.1% | $42.38B+21.3% | $34.95B+15.1% | |
| Price / earnings | 87.4×-102× | 188.9×-533× | 721.9×— | —— | —— | |
| Price / sales | 10.2×-3.9× | 14.1×-4.5× | 18.6×+1.4× | 17.2×+2.3× | 14.9×+1.4× | |
| Price / book | 40.8×-25.8× | 66.6×-189× | 255.6×+86.4× | 169.1×+87.1× | 82×-370× | |
| EV / EBITDA | 52.6×-39.2× | 91.8×-90.6× | 182.4×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's profit margins?
- Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
- Where do Alnylam Pharmaceuticals's ratios come from?
- Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
